-
Genting Xinyao Goshatuomab was awarded Orphan Drug Designation by MFDS in South Korea
Time of Update: 2021-05-22
Genting Shinyao announced today that Gosartuzumab has obtained orphan drug designation granted by South Korea’s MFDS, which is used to treat locally unresectable advanced or metastatic triple-negative breasts that have received at least two lines or more of previous treatment.
ADC drugs for adult cancer patients are still in the research stage in South Korea.
-
Osaicam Posaconazole Injection is about to pass the consistency evaluation
Time of Update: 2021-05-22
Recently, NMPA official website data shows that Osaikon’s posaconazole injection 3 types of imitation listing applications have entered the "under review" status, and it is expected to win the first domestic imitation + first review.
-
Tailong Pharmaceutical's independent director Wang Bo resigns after his term of office expires
Time of Update: 2021-05-22
Wang Bo will continue to perform independent directors and their related duties in the special committees of the board of directors.
The company will complete the by-election of independent directors as soon as possible in accordance with relevant regulations.
-
In 2020, medical insurance negotiations will increase the provision of anti-cancer drugs by 15%
Time of Update: 2021-05-22
On May 10th, Guo Yanhong, Supervisor of the Medical Administration and Hospital Administration of the National Health Commission, introduced at a press conference held on the 10th that according to the results of the monitoring network of more than 1,400 hospitals across the country, the 2020 monitoring network hospitals will be equipped The average number of varieties has increased by about 15% compared to 2019.
-
Renfu Medicine HW021199 Tablets Approved for Clinical Trial
Time of Update: 2021-05-22
HW021199 tablets are suitable for the treatment of idiopathic pulmonary fibrosis.
Only two drugs, nintedanib and pirfenidone, are approved for the treatment of idiopathic pulmonary fibrosis in the world.
-
Review of Nifedipine Sustained Release Tablets (II), a subsidiary of China Resources Double Crane
Time of Update: 2021-05-22
On May 7, China Resources Double-Crane issued an announcement stating that the subsidiary had received the Nifedipine Sustained-Release Tablets (II) "Drug Supplementary Application Approval Notice" approved and issued by the State Food and Drug Administration.
On the 20th, it was approved by the State Food and Drug Administration and passed the consistency evaluation.
-
Standardization of naming terminology facilitates the naming standard of medical device generic names
Time of Update: 2021-05-22
56 。，、、，。 ，，、、，，。 ，，，、。，、、。 、。，。 The standardization of medical device naming terms helps to standardize the general name of medical device products, improve the recognition of similar products, save regulatory resources, promote the high-quality development of the industry, and review the entire life cycle of medical device approval, production, operation, procurement, and use before the market Management is of great significance.
-
Development of farnesol receptor agonist LJN452: application examples of conformational restriction strategies
Time of Update: 2021-05-22
The compound has excellent performance in in vitro testing, but the PK data is too poor (high clearance and low bioavailability), as well as potential toxicity and light instability, mainly caused by the stilbene structure in the structure, which greatly limits the possibility of its preparation as a drug Therefore, the optimization of the stilbene structure has become the first breakthrough direction.
-
Luye Pharmaceutical's innovative compound liposome formulation completes the first patient enrollment in Phase I clinical trials
Time of Update: 2021-05-22
On April 29, Luye Pharmaceutical Group announced that its self-developed innovative anti-tumor preparation-Irinotecan Hydrochloride Liposome Injection (LY01616) has completed the first phase I clinica
-
Two departments request to speed up the direct settlement of outpatient expenses across provinces
Time of Update: 2021-05-22
" The notice requires that by the end of 2021, more than 60% of the counties in all provinces have at least one inter-provincial networked medical institution for general outpatient expenses, and the overall planning area basically realizes direct settlement of ordinary outpatient expenses across provinces.
-
Osaikang obtained the first domestic approval for posaconazole injection and has a reliable plan for sequential prevention and treatment of IFD
Time of Update: 2021-05-22
Ixuanao® enteric-coated tablets and injections have been successively approved to provide the most reliable solution for the sequential prevention and treatment of invasive fungal disease (IFD) in clinical practicePosaconazole is the latest generation of triazole antifungal drugs and the antifungal drug with the broadest antibacterial spectrum so far.
-
Centralized procurement pressures listed pharmaceutical companies to sell subsidiaries!
Time of Update: 2021-05-22
Recently, A-share listed company Nanjing Hi-Tech announced that it will publicly transfer its holding subsidiary Nanjing Chengong Pharmaceutical Co.
Finally, in January and February this year, Laimei Pharmaceuticals disposed of the assets of these four subsidiaries by means of transfer and contracting operations.
-
Personnel changes!
Time of Update: 2021-05-22
According to the latest industry news, AbbVie’s National Business Director of Immunization Division officially left before May Day to seek external development.
He joined the CC department of Bayer Pharmaceuticals in 2002 and was responsible for the hospital sales of Daxi, Kenitin and other products.
-
Pfizer CEO: Resolutely oppose the abandonment of the intellectual property rights of the new crown vaccine!
Time of Update: 2021-05-22
Abandoning intellectual property rights will make investment People are worried and will "disrupt the supply of vaccine raw materials.
Another example is that Pfizer has invested US$2 billion to develop vaccines.
-
Dilemma and Breakthrough——Thinking about the failure of China's innovative drug research and development
Time of Update: 2021-05-22
Tracking the latest research progress in the field of disease and target research, developing products with innovative mechanisms, or performing differentiated designs for existing drugs, and improving the efficacy, safety and compliance of drugs, are of great value.
-
Fosun Pharma/BioNTech establishes a joint venture company in China
Time of Update: 2021-05-22
Regarding the subsequent commercialization of the vaccine, it was agreed that the joint venture company would hire an affiliate of Fosun Pharmaceutical Industry as the CSO to provide marketing and sales services for the mRNA COVID-19 vaccine in China (excluding Hong Kong, Macao and Taiwan), and pay the CSO accordingly.
-
How many large pharmaceutical companies’ profit revenues can’t even reach the “good value”
Time of Update: 2021-05-22
Starting from Zheng Xiaoyu's large number of drug registrations, many pharmaceutical companies have experienced the days of rushing to make money by taking advantage of the asymmetry of information.
Moreover, due to factors such as medical insurance control fees, pharmaceutical companies must broaden their sales platforms, such as DTP pharmacies.
-
Carrelizumab for injection, a subsidiary of Hengrui Pharmaceuticals, obtained the "Drug Registration Certificate"
Time of Update: 2021-05-22
Up to now, the accumulated research and development expenses of carrelizumab for injection related projects are approximately RMB 1,456.
-
The State Food and Drug Administration approved the promulgation of the first batch of national standards for Chinese medicine formula granules
Time of Update: 2021-05-22
Medical Network News, April 30, April 29, the official website of the State Food and Drug Administration announced that on the basis of the preliminary work, the State Food and Drug Administration organized the National Pharmacopoeia Commission in accordance with the "Technical Requirements for the Quality Control and Standardization of Traditional Chinese Medicine Formula Granules" and the state Relevant procedures for the formulation of drug standards, and the formulation of national standards for traditional Chinese medicine formula granules.
-
Geli's new hepatitis B drug ASC22 Phase 2a Trial Announces Latest Results
Time of Update: 2021-05-22
The data shows that after a single administration of ASC22, the hepatitis B surface antigen can be reduced in patients, and it has shown good safety and tolerability.
The primary efficacy endpoint of the trial was the decline of hepatitis B surface antigen during the 12-week follow-up after a single dose.
